Business Wire

ALTASCIENCES

3.3.2021 15:43:06 CET | Business Wire | Press release

Share
Altasciences Conducts Phase I Study in Healthy Normal Subjects for RLS-0071 for Treatment of Acute Lung Injury Due to COVID-19 Pneumonia

Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza. As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada.

Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences, says, “Our teams are proud to have the opportunity to be involved in the clinical conduct and bioanalytical analysis for this important first-in-human trial. Being able to prioritize COVID-19 therapies by contributing critical data to the development of potentially life-altering medications, such as RLS-0071, is tremendously rewarding to our teams .”

Click here to read the ReAlta press release on RLS-0071, and to learn more about ReAlta Life Sciences.

“The results from our healthy volunteers study will inform our ongoing ALI study in hospitalized COVID-19 patients, as well as future programs … we look forward to obtaining data from this study as it progresses to market,” says Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer.

About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fossil Fuels Are a Thing of the Past; The Future Is Renewable: The Smarter E Europe Concludes With a Clear Message25.6.2026 19:03:00 CEST | Press release

Packed halls, a vibrant atmosphere and a buzzing vibe – after three days, The smarter E Europe 2026, Europe’s largest alliance of exhibitions for the energy industry, has come to a successful close. The event held at Messe München offered a glimpse of a future-oriented energy world powered by renewables. A strong signal with a clear message went out to the world from the Bavarian capital: The future is renewable. Renewable energies can help ensure a reliable, secure and cost-effective energy supply around the clock, seven days a week. A total of 2,650 exhibitors from 52 countries – many of whom had expanded their booth space compared with the previous year – demonstrated how this can work. More than 66 percent of exhibitors were from outside of Germany. They presented innovative and market-ready products ranging from virtual power plants, smart grid and load control, smart charging solutions, storage technologies and PV hybrid systems to digital platforms transparently and flexibly.The

HeyGen Doubles to $200M ARR in Eight Months on the Rise of Identity-First AI Video25.6.2026 18:02:00 CEST | Press release

HeyGen, the identity-first AI video platform, today announced it has surpassed $200 million in annual recurring revenue, doubling in eight months. The milestone reflects a rapid shift in how individuals, small businesses, and enterprises adopt AI video: as a scalable layer for human communication across languages, formats, and audiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625305891/en/ HeyGen passes $200M in ARR HeyGen's community now spans more than 30 million users in 196 countries and 175+ languages & dialects, from solopreneurs creating professional social videos for the first time to 85% of the Fortune 100 — who together have created more than 118 million videos. That growth has come with rare capital efficiency: HeyGen generates roughly $2.70 in ARR for every dollar of equity capital raised, making it one of the most capital-efficient venture-backed AI companies in the world. "Crossing $200 million in AR

Amazfit Brings Interactive iOS Notifications to Select Smartwatches in Europe25.6.2026 16:50:00 CEST | Press release

New Beta feature allows eligible iPhone users to reply, take action and view supported notification images directly from their wrist Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced its support of iOS Notification Forwarding, a new Beta feature that provides eligible iPhone users in the European Union with a more complete notification experience on select Amazfit smartwatches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625552705/en/ Amazfit brings interactive iOS notifications to select smartwatches in Europe, allowing users to interact with supported notifications directly from their watch. The feature goes beyond basic notification alerts, allowing users to interact with supported notifications directly from their watch. Depending on the notification type, users may be able to reply to messages, complete quick actions such as Mark as Read or Call Back, and view supported images fr

Quorum Software Acquires Streamba to Extend Leadership as the AI Platform for the Energy Value Chain25.6.2026 16:35:00 CEST | Press release

Acquisition brings Streamba's AI-native logistics platform and VOR intelligence layer into Quorum’s unified energy data – closing the loop between planning, field execution and supply chain in real time Quorum Software, a global leader in energy software, today announced the acquisition of Streamba, an AI-native supply chain platform purpose-built for energy. This acquisition advances Quorum's position as the AI platform for the energy industry — embedding intelligent, real-time orchestration across upstream, midstream, measurement, SCADA and supply chain. For the first time, energy operators can connect planning, execution and back office in a single, AI-powered system. Quorum has built a comprehensive energy software platform through sustained innovation and strategic acquisitions, spanning planning, production operations, measurement, accounting, hydrocarbon management and logistics. Streamba’s Visibility, Orchestration and Response (VOR) platform adds a centralized operational inte

Clearwater Analytics Completes $8.4 Billion Take-Private Acquisition by Permira and Warburg Pincus25.6.2026 16:07:00 CEST | Press release

Acquisition supported by Francisco Partners, with participation from TemasekStockholders receive $24.55 per share Clearwater Analytics (“CWAN”, “Clearwater” or the “Company”), today announced the completion of its previously announced acquisition, a transaction valued at approximately $8.4 billion, by a Permira and Warburg Pincus-led Investor Group (the “Investor Group”). The transaction was supported by Francisco Partners, with participation from Temasek. With the completion of the acquisition, Clearwater’s Class A common stock no longer trades on the New York Stock Exchange. Under the terms of the agreement, Clearwater stockholders received $24.55 per share in cash, representing an approximately 47% premium over the Company’s undisturbed share price on November 10, 2025, the last trading day prior to media reports regarding a potential transaction. The transaction followed a thorough review process overseen by a Special Committee of independent and disinterested members of the Clearw

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye